


HEALTHCARE

## **The Biotechnology Market Outlook**

Growth opportunities and effective strategies for licensing and collaborations

By Gayle Hamilton

 [Table of Contents](#)

## **Gayle Hamilton**

Gayle Hamilton is an analyst within the healthcare function of Business Insights, and has written previous titles on the Diabetes, Antivirals and Vaccines markets, as well as Anti-Counterfeiting Strategies. Gayle also wrote the recently launched Pharmaceutical Market Outlook to 2015.

Gayle previously worked in several R&D roles in the pharmaceutical and biotech industries, at Celltech (now part of UCB), Genzyme Corporation in the US, and Procter & Gamble, and graduated with a Masters degree in Biochemical Engineering from University College London.

Copyright © 2005 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Biotechnology Market Outlook to 2015

<b>Executive Summary</b>	<b>10</b>
Biotechnology industry status	10
The biotechnology market	11
Drivers and resistors of market growth	12
Biotech growth strategies	13
Changing relationship with pharma and biotech	14
<b>Chapter 1           Biotechnology industry status</b>	<b>16</b>
Summary	16
Introduction	17
Stock market performance	19
Growth of biotech sales	20
Sector growth to 2015	21
Increase in biotech research	23
Increase in biotech product approvals	24
<b>Chapter 2           The biotechnology market</b>	<b>28</b>
Summary	28
Introduction	29
Biotechnology in the major markets	30
Biotech drug groupings	32
Leading drug categories by ATC class	34
Human insulin and analogues	36
Erythropoietins	36
Interferons	37
Special antirheumatic agents	37
Other cytostatics and immunosuppressive agents	38

Monoclonal antibodies	38
<b>Leading therapeutic areas for biotech products</b>	<b>41</b>
<b>Leading brands in the biotech market</b>	<b>42</b>
<b>Competitive landscape</b>	<b>43</b>
Top 10 pharma/biotech companies by biotech sales	43
Top 10 biotech companies by total sales	44
Segmentation of biotech companies	46
<b>Chapter 3</b>	<b>Drivers and resistors of market growth</b>
	<b>50</b>
<b>Summary</b>	<b>50</b>
<b>Introduction</b>	<b>51</b>
<b>Drivers of market growth</b>	<b>51</b>
Innovation gap in pharma R&D	52
Patent expiries of pharma's blockbuster drugs	55
Higher approval rates for biotech products	56
Diagnostic innovation	57
Fulfilling unmet ideas	59
Advancements in enabling technologies	60
Increased investor confidence	62
<b>Resistors of market growth</b>	<b>63</b>
Government cost containment and reimbursement	64
Biogenerics	67
Development of sales and marketing capabilities	71
Complex regulations	72
Analyst perception and access to funding	73
Public perception/ethics	74
<b>Chapter 4</b>	<b>Biotech growth strategies</b>
	<b>78</b>
<b>Summary</b>	<b>78</b>
<b>Introduction</b>	<b>79</b>
<b>Technology providers and developers</b>	<b>81</b>
Successful growth strategies	81
Strategy 1: Become an acquisition target	82
Strategy 2: Independent operation through IPO and out-licensing	82
<b>Early-stage drug developers</b>	<b>83</b>
Successful growth strategies	83
<b>Late-stage drug developers</b>	<b>84</b>
Successful growth strategies	85
<b>Fully integrated players</b>	<b>85</b>

Successful growth strategies	86
<b>Growth from an embryonic to integrated biotech</b>	<b>87</b>
Case study: Millennium Pharmaceuticals	87
<b>Chapter 5</b>	<b>Changing relationship between pharma &amp; biotech</b>
	<b>94</b>
Summary	94
Introduction	95
Mergers and acquisitions	97
Pharma-biotech M&A	97
Biotech-biotech M&A	98
Biotech spinouts	98
Licensing and alliance deals	100
Pharma-biotech licensing and alliances	100
Biotech-biotech licensing and alliances	106
Conclusions	108
<b>Chapter 6</b>	<b>Appendix</b>
	<b>110</b>
Primary research methodology	110
Index	112

# List of Figures

Figure 1.1:	History of biotechnology, 1971-2005	17
Figure 1.2:	NASDAQ biotech index, 1995-2005	19
Figure 1.3:	Biotech sector as share of total pharmaceutical market, 2000-2004	21
Figure 1.4:	Industry prediction of future sector annual growth rates to 2015	22
Figure 1.5:	Active biotech projects in development, 2004	23
Figure 1.6:	US approvals of small molecule drugs and biological therapies, 1994-2003	25
Figure 2.7:	Industry growth rates in the biotech and pharma sectors, 2000-04	29
Figure 2.8:	Market maturity and annual market growth rate	30
Figure 2.9:	Geographical split of the biotech market, 2004	32
Figure 2.10:	Forecast change in product launch activity by drug category to 2015	34
Figure 2.11:	Biotech market share by ATC class in Europe, 2000 & 2004	35
Figure 2.12:	New launches by therapeutic area to 2015	41
Figure 2.13:	Competitive positioning in the biotech market, 2004	46
Figure 2.14:	Biotech companies at different stages of growth	47
Figure 3.15:	Drivers of biotech industry growth	52
Figure 3.16:	Innovation gap in pharmaceutical R&D, 1999-2004	53
Figure 3.17:	Blockbuster US patent expiries, 2004-11	55
Figure 3.18:	Comparative approval success rates of US biopharmaceutical products and drugs	56
Figure 3.19:	The first diagnostic array - AmpliChip	58
Figure 3.20:	Sources of finance in the US biotech industry, 2000-04	62
Figure 3.21:	Resistors of biotechnology market growth	63
Figure 3.22:	Annual change in national spending for selected health services (%), 1993-2003	64
Figure 3.23:	Estimated exposure to biogenerics by company, 2005-2010	71
Figure 3.24:	Absolute and proportional promotional expenses, 2000-2003	72
Figure 4.25:	The lifecycle of a biotech company	80
Figure 4.26:	Millennium SWOT analysis, 2005	90
Figure 5.27:	Alternative growth strategies for biotech companies	96
Figure 5.28:	Advantages of spin out companies	99
Figure 5.29:	Attrition rates in pharmaceutical R&D by phase	101
Figure 5.30:	Number of total and new drug discovery deals for the top 20 companies, Sep 2002 – Mar 2004)	104
Figure 5.31:	Impact of alliances on future drug development	105
Figure 6.32:	Survey respondents by job function	110
Figure 6.33:	Survey respondents by type of company and stage of biotech funding	111

# List of Tables

Table 1.1:	Biotech and pharma sales globally, 2000-2004	20
Table 2.2:	Groupings of biotechnology products	33
Table 2.3:	Global sales of antibody drugs (\$m), 2004	39
Table 2.4:	Top 10 biotech brands globally (\$m), 2004	42
Table 2.5:	Top 10 companies selling biotech products, 2004	44
Table 2.6:	Top 10 biotech companies, 2004	45
Table 3.7:	Public expenditure on healthcare, 2000	66
Table 3.8:	Key biologic medicines, sales and estimated risk of generic competition, 2005-2010	68
Table 3.9:	Key characteristics that determine level of risk from biogeneric competition in high risk therapeutic areas	69
Table 5.10:	Major pharmaceutical M&A activity, 2003-04	97
Table 5.11:	Pharma biotech deals, June 2004 – June 05	103
Table 5.12:	Serono's licensing and alliance activity, 2004-July 2005	107